Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,264 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pathways Clear all
Completed Phase 2Phase 3 Interventional Results available

Long Term Extension Trial of Setmelanotide

NCT03651765
View directory record Official record
Conditions
Obesity Associated With Defects in Leptin-melanocortin Pathway
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Chandler, Arizona • Scottsdale, Arizona • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 18, 2026, 7:28 AM EDT
Terminated Phase 3 Interventional Results available

Muscadine Plus (MPX) In Men With Prostate Cancer

NCT03535675
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Muscadine Plus, Placebos
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Duarte, California • La Jolla, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 18, 2026, 7:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Effects of Metabolic & Bariatric Surgery on Lipid Metabolism, Myeloid-Derived Suppressor Cells, and Cancer Cell Biology

NCT06059651
View directory record Official record
Conditions
Obesity
Interventions
Metabolic & Bariatric Surgery
Procedure
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
35 Years to 60 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 18, 2026, 7:28 AM EDT
Completed No phase listed Observational

Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia

NCT01150669
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 2 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 18, 2026, 7:28 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss

NCT07472023
View directory record Official record
Conditions
Sensorineural Hearing Loss, Tinnitus, Acoustic Trauma, Inner Ear Injury, Noise-Induced Hearing Loss, Sudden Hearing Loss, Vestibular Dysfunction
Interventions
Audiologic Monitoring, Investigational Regenerative Pharmacologic Therapy, Stem Cell Regenerative Therapy, Combination Regenerative Therapy
Other · Drug · Biological + 1 more
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2099
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 18, 2026, 7:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

NCT01989546
View directory record Official record
Conditions
Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors
Interventions
BMN 673
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 18, 2026, 7:28 AM EDT
Terminated Phase 1 Interventional

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

NCT01208441
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
letrozole, gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, breast biopsy, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 18, 2026, 7:28 AM EDT
Recruiting Phase 2 Interventional

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

NCT07223385
View directory record Official record
Conditions
Prostate Cancer (Diagnosis), Prostate Cancer Stage IV, CV Risk
Interventions
Cardio-Oncology Referral, Notification to PCP/General Cardiologist
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
45 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 18, 2026, 7:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Infusion Flow Rates and Blood Sampling

NCT02021617
View directory record Official record
Conditions
Intraosseous Access, Infusion Rates, Intraosseous Blood, Venous Blood
Interventions
Intraosseous access
Device
Lead sponsor
Vidacare Corporation
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Spring Branch, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 18, 2026, 7:28 AM EDT
Completed Not applicable Interventional Results available

Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer

NCT02517268
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Pancreaticoduodenectomy
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 18, 2026, 7:28 AM EDT
Recruiting Phase 1 Interventional

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

NCT07224776
View directory record Official record
Conditions
Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
Interventions
sparsentan, No sparsentan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 18, 2026, 7:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients

NCT01769768
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
LDE225, Wafarin, Bupropion
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
13
States / cities
Duarte, California • Kansas City, Kansas • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 18, 2026, 7:28 AM EDT
Terminated Not applicable Interventional

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

NCT05812274
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 18, 2026, 7:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

NCT05054374
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma, MEK1 Gene Mutation, MEK2 Gene Mutation, Metastatic Breast Cancer
Interventions
Mirdametinib, Fulvestrant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 18, 2026, 7:28 AM EDT
Not yet recruiting Not applicable Interventional

Measurement-Based Care to Support Buprenorphine-Naloxone Treatment in Outpatient Addiction Clinics

NCT07839182
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Bup-MBC
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 7:28 AM EDT
Completed Not applicable Interventional Results available

CB3 Pilot (Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia)

NCT05697380
View directory record Official record
Conditions
Aphasia, Primary Progressive Aphasia, Dementia, Communication, Alzheimer Disease
Interventions
Communication Bridge™
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 18, 2026, 7:28 AM EDT
Completed Phase 1Phase 2 Interventional

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

NCT03543189
View directory record Official record
Conditions
Prostate Cancer, Prostate Disease
Interventions
Nivolumab, Brachytherapy, External Beam Radiation Therapy, Androgen Deprivation Therapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 18, 2026, 7:28 AM EDT
Recruiting Not applicable Interventional

Motor-Cognitive Training for Motoric Cognitive Risk Syndrome

NCT07223905
View directory record Official record
Conditions
Motoric Cognitive Risk Syndrome
Interventions
Virtual Reality Treadmill Training, Treadmill Training
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 7:28 AM EDT
Completed Early Phase 1 Interventional

Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome

NCT05377112
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
SYNB8802v1, Placebo
Drug · Other
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 18, 2026, 7:28 AM EDT
Completed Phase 3 Interventional Results available

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

NCT03746522
View directory record Official record
Conditions
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
San Diego, California • Springfield, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 18, 2026, 7:28 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Perinatal Autism Genetics and Epigenetics Study

NCT07738003
View directory record Official record
Conditions
Autism Disorders and Maternal Stress, Development Delay, Prenatal Stress, Social Behavior
Interventions
Change in child's DNA methylation, Perinatal stress, Early social experience, Polygenic risk scores for social communication and repetitive behavior
Genetic · Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
0 Years to 50 Years
Enrollment
7,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 18, 2026, 7:28 AM EDT
Completed Not applicable Interventional

Enhanced Recovery After Surgery in Laparoscopic Sleeve Gastrectomy

NCT03520803
View directory record Official record
Conditions
Obesity
Interventions
Enhanced recovery after surgery protocol
Other
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 18, 2026, 7:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index

NCT02663661
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Metabolic Challenge Admission, CGM home test
Procedure · Other
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 45 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 18, 2026, 7:28 AM EDT
Recruiting Phase 1 Interventional

SW-682 in Advanced Solid Tumors

NCT06251310
View directory record Official record
Conditions
Advanced Solid Tumor, Mesothelioma, Malignant
Interventions
SW-682, Combination Therapy
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 18, 2026, 7:28 AM EDT